April 27, 2020 / 11:36 AM / a month ago

BRIEF-Cti Biopharma Announces Initiation Of Phase 3 Pre-Vent Study Evaluating Pacritinib In Hospitalized Patients With Severe Covid-19

April 27 (Reuters) - CTI Biopharma Corp:

* CTI BIOPHARMA ANNOUNCES INITIATION OF PHASE 3 PRE-VENT STUDY EVALUATING PACRITINIB IN HOSPITALIZED PATIENTS WITH SEVERE COVID-19

* CTI BIOPHARMA - EXPECTS TO COMMENCE ENROLLMENT OF PRE-VENT IN MAY AT SITES IN U.S., EUROPE WITH DATA EXPECTED BY END OF 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below